Leonid Zeitlin

Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline

Anti-inflammatory effects of long-chainn-3 PUFA in rhinovirus-infected cultured airway epithelial cells

Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine

WNT signaling in bone homeostasis and disease: from human mutations to treatments

The Epidemiology of Distal Radius Fractures

Williams–Beuren Syndrome

Graft-versus-host disease

Comparison of Radiographic Fracture Healing in the Distal Radius for Patients on and off Bisphosphonate Therapy

Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study

Saturation in qualitative research: exploring its conceptualization and operationalization

Unexplained fractures in infancy: looking for fragile bones

The Evaluation of Suspected Child Physical Abuse

Bisphosphonate Therapy for Reduced Bone Mineral Density in Children with Chronic Graft-versus-Host Disease

Three Years Follow-up of Pamidronate Therapy in Two Brothers with Osteoporosis-Pseudoglioma Syndrome (OPPG) Carrying an LRP5 Mutation

Severe Infantile Hypercalcemia Associated With Williams Syndrome Successfully Treated With Intravenously Administered Pamidronate

Controlled Trial of Pamidronate in Children With Types III and IV Osteogenesis Imperfecta Confirms Vertebral Gains but Not Short-Term Functional Improvement

American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update

Effects of long‐term administration of N‐3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice

The effect of cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta Type V

Osteogenesis Imperfecta Types I, III, and IV: Effect of Pamidronate Therapy on Bone and Mineral Metabolism

Delayed Osteotomy but Not Fracture Healing in Pediatric Osteogenesis Imperfecta Patients Receiving Pamidronate

Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV